Breaking News

UPM, Amerigen Enter Long-Term Mfg. Pact

April 21, 2014

Will supply two products under 10-year supply pact

UPM, a division of Gregory Pharmaceutical Holdings, Inc., has entered an agreement with Amerigen Pharmaceuticals, Inc. to manufacture two ANDA products for a 10- year commercial supply term. Also, UPM may potentially develop and supply several additional ANDA products for Amerigen under the agreement.  

Back in July 2013, UPM acquired Pfizer’s 475,000 sq.-ft. manufacturing facility in Bristol, TN, which is where all of these products will eventually be made.  

Dr. John M. Gregory, chairman and chief executive officer of Gregory Pharmaceutical Holdings, Inc., said, "UPM has been working with Amerigen for the past three years. We have a strong working relationship with their company and are impressed with their technical team and their business development approach. We believe this agreement cements our partnership with Amerigen. Also, it is another example of UPM's transition from a company that formerly focused on only early stage development, but now, provides a full range of solid dose commercial services for our clients."  

Jonathan Embleton, chief business officer of Amerigen, said, "Amerigen looks forward to a long relationship with UPM.  We are excited about our upcoming product portfolio and the role UPM will play in providing products to market."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks